OKYO Pharma Limited (OKYO)
Company Description
OKYO Pharma is a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.
Our research program is focused on a novel G Protein-Coupled Receptor, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need.
Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate, for the treatment of dry-eye disease.
We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical analogue candidate that is currently in developmental stage.
| Country | United Kingdom |
| Founded | 2007 |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 6 |
| CEO | Dr. Gary S. Jacob |
Contact Details
Address:
Martello Court, Admiral Park St. Peter Port GY1 3HB Guernsey | |
| Phone | 44 20 7495 2379 |
| Website | okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | US Dollars |
| IPO Price | $4.00 |
| CIK Code | 1849296 |
| ISIN Number | US6793451088 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer and Executive Director |
| Michael Paul Beck | Founder |
| Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 9, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 20, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 20, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 19, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 19, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 19, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 18, 2022 | 4/A | Statement of changes in beneficial ownership of securities |
| May 18, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 18, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 18, 2022 | 424B4 | Prospectus [Rule 424(b)(4)] |